Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest International Prostate Symptom Score Stories

2013-05-06 16:27:26

Results from Large Randomized Trial Support Use of Innovative 180 Watt Laser Therapy as a Viable Treatment Option for More Than 110 Million Men Worldwide with Enlarged Prostate MINNETONKA, Minn., May 6, 2013 /PRNewswire/ -- Data to be presented tomorrow at the American Urological Association (AUA) Annual Meeting demonstrate that treatment for Benign Prostatic Hyperplasia (BPH) with GreenLight XPS(®) laser therapy with MoXy(®) fiber, instead of transurethral resection of the...

2012-10-09 07:27:06

Single administration of PRX302 as a short outpatient procedure provided sustained benefit over 12 months SAN DIEGO, CA and VANCOUVER, Oct. 9, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS) today released top line data from the 12 month follow up of patients receiving PRX302 for the treatment of benign prostatic hyperplasia (BPH, or enlarged prostate) in a Phase 2b study (TRIUMPH). PRX302 produced a clinically significant improvement in the subjective symptom score (International...

2012-08-31 02:24:41

SAN DIEGO, CA and VANCOUVER, Aug. 31, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS) today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection. The results support the use of a transrectal ultrasound (TRUS) guided injection for the delivery of PRX302 directly into the prostate. This route...

2012-05-11 23:03:18

The use of saw palmetto in patients with benign prostatic hyperplasia (BPH) improves not only urinary symptoms but also concomitant sexual dysfunctions, latest research shows. Roggwil, Switzerland (PRWEB) May 11, 2012 A new study — published in the journal Phytotherapy Research -- showed for the first time that a treatment with a saw palmetto preparation (Prostasan®) lead to an improvement not only of urinary symptoms but also of sexual dysfunctions.Benign prostatic hyperplasia...

2012-02-07 07:00:00

INDIANAPOLIS, Feb. 7, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that a Phase III study, published online by European Urology, showed both Cialis® (tadalafil) and tamsulosin significantly improved scores on the International Prostate Symptom Score (IPSS), compared to placebo, in men with signs and symptoms suggestive of benign prostatic hyperplasia (BPH). Cialis improved erectile dysfunction (ED) in those men who had both signs and symptoms of BPH...

2012-01-09 09:15:00

PLEASANTON, Calif., Jan. 9, 2012 /PRNewswire/ -- NeoTract, Inc., a medical device company developing new urology devices, today announced completion of enrollment in the FDA-approved L.I.F.T. Study for men with urinary tract symptoms due to benign prostatic hyperplasia (BPH). This multi-national study enrolled 206 men, age 50 or older, and was randomized 2:1 to the UroLift® System versus control. The UroLift System is being investigated as a minimally invasive device designed to...

2011-10-06 15:58:00

SILVER SPRING, Md., Oct. 6, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. Cialis was approved in 2003 for the treatment of ED. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Common symptoms...

2011-03-22 08:10:00

PLEASANTON, Calif., March 22, 2011 /PRNewswire/ -- NeoTract, Inc. a medical device company focused on developing urology devices, today announced that the first U.S. patients have been enrolled in a multinational trial of its UroLift® System at Western Urological Clinic in Salt Lake City, Utah. The UroLift System is a minimally invasive approach to treating benign prostatic hyperplasia (BPH) that lifts prostate tissue out of the way so that it no longer blocks the...

2010-03-02 12:56:28

DALLAS -- Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center. The findings, published in a recent issue of the journal European Urology, compared treatments for three groups of study participants with enlarged prostates over four years. The study, which included more than 4,800 men, is one of the first to compare single...

2010-01-06 07:00:00

WALTHAM, Mass., Jan. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that GlaxoSmithKline's Duodart (the fixed-dose combination of dutasteride and tamsulosin) will earn Decision Resources' proprietary clinical gold standard status in 2013 and through 2018 for the treatment of benign prostatic hyperplasia/male lower urinary tract symptoms due to its competitive advantage in overall efficacy over...